Glenmark Pharma to Launch Sodium Phosphates Injection USP in the US Market

Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Limited, has announced the upcoming launch of Sodium Phosphates Injection USP in multiple single-dose vial presentations in the United States. 

The launch represents another milestone in the company’s strategy to expand its institutional product portfolio while providing affordable therapeutic alternatives in the injectable medicines segment. Distribution of the product is expected to commence in April 2026.

Product Overview and Regulatory Status

The Sodium Phosphates Injection USP will be introduced in three strengths: 15 mM P/5 mL, 45 mM P/15 mL, and 150 mM P/50 mL (3 mM P/mL) single-dose vials. Glenmark’s formulation has been confirmed as bioequivalent and therapeutically equivalent to the reference listed drug Sodium Phosphates Injection USP, 45 mM P/15 mL, marketed by Hospira, Inc.

The additional dosage presentations are expected to deliver the same therapeutic effect as the reference drug, based on safety and efficacy evaluations relied upon by the US Food and Drug Administration (FDA). The product will be marketed strictly for the indications approved under Glenmark’s label.

Market Opportunity

According to IQVIA sales data for the 12-month period ending December 2025, the Sodium Phosphates Injection market recorded annual sales of approximately $66.8 million in the United States. This reflects a meaningful opportunity for Glenmark to expand its presence within hospital and institutional healthcare channels.

The injectable generics segment continues to witness steady demand due to increased hospital usage and the growing need for cost-effective treatment options.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “We look forward to the upcoming launch of Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials, strengthening our commitment to bring to market quality and affordable alternatives for patients, while also further expanding our portfolio of products within the institutional channel.”

Glenmark Share Price Performance

On February 27, 2026, Glenmark share price opened at ₹2,125.60. At 11:03 AM, the share price of Glenmark was trading at ₹2,138.10, up by 0.72% on the NSE.

Also Read: Best Pharma Stocks in February 2026!

Conclusion

The upcoming launch of Sodium Phosphates Injection USP marks a strategic expansion for Glenmark in the US pharmaceutical market. By entering a multi-million-dollar injectable segment with a therapeutically equivalent product, the company enhances its institutional offerings while supporting improved access to affordable healthcare solutions. The move highlights Glenmark’s continued emphasis on growth in regulated markets through portfolio diversification.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.